Results 11 to 20 of about 4,077,149 (265)

Sunitinib for advanced renal cell cancer

Biologics: Targets & Therapy, 2008
Chris CoppinBC Cancer Agency and University of British Columbia, Vancouver, CanadaAbstract: Renal cell cancer has been refractory to drug therapy in the large majority of patients.
Chris Coppin
doaj   +1 more source

Differential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcome [PDF]

, 2013
Renal cell carcinoma (RCC) is the most deadly of urological malignancies. Metastatic disease affects one third of patients at diagnosis with a further third developing metastatic disease after extirpative surgery.
Antony C P Riddick, Stewart Grant D., Laird Alexander, Alexander Laird, Grant D Stewart, Laird, Alexander, O'Mahony, Fiach C, Riddick, Antony C P, Riddick Antony C. P., O’Mahony Fiach C., Harrison David J., Fiach C O'Mahony, Jyoti Nanda, Harrison, David J, David J Harrison, O'Mahony, Fiach C., Riddick, Antony C. P., Nanda Jyoti, Nanda, Jyoti, Stewart, Grant D., O’Donnell Marie, O'Donnell, Marie, Stewart, Grant D, Marie O'Donnell, Harrison, David J.   +24 more
core   +2 more sources

Quantitative proteomics in resected renal cancer tissue for biomarker discovery and profiling [PDF]

, 2014
BACKGROUND: Proteomics-based approaches for biomarker discovery are promising strategies used in cancer research. We present state-of-art label-free quantitative proteomics method to assess proteome of renal cell carcinoma (RCC) compared with noncancer ...
J T-J Huang, Bray, S E, Fleming, S., Lamont, D J, D J Lamont, Zakikhani, P, P Zakikhani, M A V Mudaliar, Atrih, A, S Fleming, Zakikhani, P., Lamont, D. J., Barton, G.; id_orcid, G Nabi, G Barton, A Atrih, Bray, S. E., Barton, G, Huang, J. T.-J.; id_orcid, Mudaliar, M. A. V., Atrih, A., Fleming, S, Nabi, G, Nabi, G., Huang, J T-J, S E Bray, Mudaliar, M A V   +26 more
core   +1 more source

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer [PDF]

, 2008
Background Enhanced activity of histone deacetylases (HDAC) is associated with more aggressive tumour behaviour and tumour progression in various solid tumours.
Dietel Manfred, Fritzsche, Florian R., Weichert Wilko, Gekeler Volker, Dietel, Manfred, Fritzsche Florian R, Beckers Thomas, Kristiansen Glen, Jung, Klaus, Kristiansen, Glen, Weichert, Wilko, Jung Klaus, Scholman Katharina, Gekeler, Volker, Denkert Carsten, Röske, Annika, Röske Annika, Beckers, Thomas, Stephan, Carsten, Stephan Carsten, Scholman, Katharina, Denkert, Carsten Michael   +21 more
core   +1 more source

Current strategies to diagnose and manage positive surgical margins and local recurrence after partial nephrectomy

Asian Journal of Urology, 2022
Objective: No standard strategy for diagnosis and management of positive surgical margin (PSM) and local recurrence after partial nephrectomy (PN) are reported in literature.
Umberto Carbonara, Daniele Amparore, Cosimo Gentile, Riccardo Bertolo, Selcuk Erdem, Alexandre Ingels, Michele Marchioni, Constantijn H.J. Muselaers, Onder Kara, Laura Marandino, Nicola Pavan, Eduard Roussel, Angela Pecoraro, Fabio Crocerossa, Giuseppe Torre, Riccardo Campi, Pasquale Ditonno   +16 more
doaj   +1 more source

Correction to: Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy

Journal of Translational Medicine, 2019
Following publication of the original article [1], the authors reported errors in Figures 2, 3 and Figure 3 ‘continued’
Longwen Xu, Zhiyuan Cheng, Chuanliang Cui, Xiaowen Wu, Huan Yu, Jun Guo, Yan Kong   +6 more
doaj   +1 more source

Lysyl oxidase inhibitors attenuate cyclosporin A-induced nephropathy in mouse

Scientific Reports, 2021
Calcineurin inhibitors, such as Cyclosporin (CsA), are the mainstay of anti-rejection therapy in solid organ transplants but can paradoxically induce progressive nephropathy characterised by renal dysfunction and interstitial fibrosis.
Long T. Nguyen, Sonia Saad, Ying Shi, Rosy Wang, Angela S. Y. Chou, Anthony Gill, Yimin Yao, Wolfgang Jarolimek, Carol A. Pollock   +8 more
doaj   +1 more source

Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure

Translational Oncology, 2018
OBJECTIVE: Asian melanoma patients, predominantly comprised of acral and mucosal subtypes, might not benefit from immunotherapy and targeted therapy as much as Caucasian patients.
ChuanLiang Cui, Li Zhou, Bin Lian, Lu Si, XiNan Sheng, ZhiHong Chi, Yan Kong, Xuan Wang, BiXia Tang, LiLi Mao, SiMing Li, Jie Dai, XieQiao Yan, Xue Bai, Jun Guo   +14 more
doaj   +1 more source

Efficacy and Safety of Paclitaxel, Ifosfamide and Cisplatin as First-line Treatment on Patients with Intermediate- or Poor-risk Advanced Testicular Cancer

Zhongliu Fangzhi Yanjiu, 2018
Objective To assess the efficacy and safety of paclitaxel, ifosfamide and cisplatin (TIP) as the first-line treatment for the patients with intermediate- or poor-risk testicular cancer retrospectively.
ZHOU Li, CHI Zhihong, CUI Chuanliang, SHENG Xi'nan, SI Lu, TANG Bixia, MAO Lili, WANG Xuan, YAN Xieqiao, LIAN Bin, LI Siming, BAI Xue, GUO Jun   +12 more
doaj   +1 more source

Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study

BMC Cancer, 2023
Background Pucotenlimab is a novel recombinant humanized anti-PD-1 (Programmed death-1) monoclonal antibody, which belongs to the human IgG4/kappa subtype, and can selectively block the binding of PD-1 with its ligands PD-L1 and PD-L2.
Chuanliang Cui, Yu Chen, Zhiguo Luo, Zhengyun Zou, Yu Jiang, Hongming Pan, Qingxia Fan, Jianfu Zhao, Qing Xu, Renbing Jiang, Xuan Wang, Taiyang Ma, Zhen Guo, Lu Si, Zhihong Chi, Xinan Sheng, Yiwei Dou, Qian Tan, Di Wu, Jun Guo   +19 more
doaj   +1 more source